ATLANTA, Aug. 7, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah), a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Ewing, N.J.-based Navinta, LLC (Navinta) announced today that Tikvah has entered into an exclusive worldwide licensing agreement that encompasses unique solution formulations, including a proprietary formulation of sodium phenylbutyrate, and methods of use and treatments of a variety of neurodegenerative disorders including, amongst others, spinal muscular atrophy, amyotrophic lateral sclerosis and multiple sclerosis, and certain metabolic disorders.
